share_log

Femasys | 10-K: Annual report

Femasys | 10-K: Annual report

Femasys | 10-K：年度報表
SEC announcement ·  03/29 10:39
牛牛AI助理已提取核心訊息
Femasys, a biomedical company specializing in women's reproductive health solutions, has reported a decrease in sales for the year ended December 31, 2023. Sales dropped by 11.1% to $1,071,970 from $1,206,218 in the previous year, attributed to a 7.0% decrease in U.S. sales and a 49.9% decrease in international sales. Despite the decline in sales, the company has made significant progress in product development and regulatory approvals. Femasys received FDA clearance for its artificial insemination solution, FemaSeed, and began commercial launch in March 2024. The company also announced the initiation of the FINALE pivotal trial for its non-surgical permanent birth control solution, FemBloc. Looking ahead, Femasys plans to continue its clinical trials, seek regulatory approvals, and expand commercialization efforts. The company's financial position remains stable with sufficient cash to fund operations into the second half of 2025, although additional funding will be necessary to complete product development and commercialization.
Femasys, a biomedical company specializing in women's reproductive health solutions, has reported a decrease in sales for the year ended December 31, 2023. Sales dropped by 11.1% to $1,071,970 from $1,206,218 in the previous year, attributed to a 7.0% decrease in U.S. sales and a 49.9% decrease in international sales. Despite the decline in sales, the company has made significant progress in product development and regulatory approvals. Femasys received FDA clearance for its artificial insemination solution, FemaSeed, and began commercial launch in March 2024. The company also announced the initiation of the FINALE pivotal trial for its non-surgical permanent birth control solution, FemBloc. Looking ahead, Femasys plans to continue its clinical trials, seek regulatory approvals, and expand commercialization efforts. The company's financial position remains stable with sufficient cash to fund operations into the second half of 2025, although additional funding will be necessary to complete product development and commercialization.
專門從事女性生殖健康解決方案的生物醫學公司Femasys報告稱，截至2023年12月31日的年度銷售額有所下降。銷售額從去年的1,206,218美元下降了11.1％，至1,071,970美元，這要歸因於美國銷售額下降了7.0％，國際銷售額下降了49.9％。儘管銷售額下降，但該公司在產品開發和監管批准方面取得了重大進展。Femasys的人工授精解決方案FemaSeed獲得了美國食品藥品管理局的批准，並於2024年3月開始商業上市。該公司還宣佈啓動其非手術永久節育解決方案FemBLOC的FINALE關鍵試驗。展望未來，Femasys計劃繼續進行臨床試驗，尋求監管部門的批准，並擴大商業化工作。儘管需要額外資金來完成產品開發和商業化，但該公司的財務狀況保持穩定，有足夠的現金爲2025年下半年的運營提供資金。
專門從事女性生殖健康解決方案的生物醫學公司Femasys報告稱，截至2023年12月31日的年度銷售額有所下降。銷售額從去年的1,206,218美元下降了11.1％，至1,071,970美元，這要歸因於美國銷售額下降了7.0％，國際銷售額下降了49.9％。儘管銷售額下降，但該公司在產品開發和監管批准方面取得了重大進展。Femasys的人工授精解決方案FemaSeed獲得了美國食品藥品管理局的批准，並於2024年3月開始商業上市。該公司還宣佈啓動其非手術永久節育解決方案FemBLOC的FINALE關鍵試驗。展望未來，Femasys計劃繼續進行臨床試驗，尋求監管部門的批准，並擴大商業化工作。儘管需要額外資金來完成產品開發和商業化，但該公司的財務狀況保持穩定，有足夠的現金爲2025年下半年的運營提供資金。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

獨立文件7  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。